Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Phase I Dose-finding Study of BI 765179 as Monotherapy and in Combination With Ezabenlimab (BI 754091) in Patients With Advanced Solid Cancers

X
Trial Profile

An Open Label, Phase I Dose-finding Study of BI 765179 as Monotherapy and in Combination With Ezabenlimab (BI 754091) in Patients With Advanced Solid Cancers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 765179 (Primary) ; Ezabenlimab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Brain metastases; Carcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant-mesothelioma; Mesothelioma; Mouth neoplasm; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Skin cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 02 Apr 2024 Planned End Date changed from 25 Nov 2026 to 27 Jan 2027.
    • 02 Apr 2024 Planned primary completion date changed from 7 Feb 2026 to 26 Apr 2026.
    • 27 Dec 2023 Planned End Date changed from 30 Mar 2026 to 25 Nov 2026.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top